Federal Ministry of Health, Germany Report issue

Government Phase 3 Phase 4

Organization Overview

First Clinical Trial
2002
NCT00268814
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Federal Ministry of Health, Germany

Active Ingredients

Drugs in Phase 4 Trials (2)

empagliflozin (jardiance) (1 trial)

semaglutide (Ozempic) (1 trial)

Drugs in Phase 3 Trials (2)

diacetylmorphine (1 trial)

methadone (methadose) (1 trial)

Drugs in Other Trials (1)

galantamine (reminyl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Fatty Liver (Phase 4)

Liver Diseases (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 4)

Opioid-Related Disorders (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5